Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
This article was originally published in The Tan Sheet
Executive Summary
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson
You may also be interested in...
FDA Morale Improvement Will Be A Priority, Von Eschenbach Testifies
Acting Commissioner Andrew von Eschenbach stressed his commitment to improving agency morale during his confirmation hearing
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B
FDA Panels Debate Pricing, Promotions For Plan B OTC
Barr Laboratories' efforts to increase access to its emergency contraceptive Plan B should include measures to make the drug accessible to women who cannot afford the morning-after pill, some panelists said at a joint meeting of the Nonprescription Drugs and Reproductive Health Drugs advisory committees in Gaithersburg, Md. Dec. 16